Jayesh Desai

Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma

Angela Mweempwa, Huiling Xu, Joseph HA Vissers, Richard W Tothill, Andrew D Pattison, Andrew P Fellowes, David M Thomas, Gary Richardson, Rodney J Hicks, Sean M Grimmond, Stephen B Fox, Stephen J Luen, Jayesh Desai, Benjamin J Solomon

Journal article  |  2021  |  JCO Precision Oncology

SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib cetuximab /- binimetinib in BEACON CRC

D Aderka, S Kopetz, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, J Desai, F Ciardiello, A Golden, M Edwards, J Tabernero

Conference Proceedings  |  2021  |  Annals of Oncology

P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data

C Li, A Ferro, S Mhatre, D Lu, M Lawrance, S Li, S Allen, J Desai, M Fakih, T Kim, I Reyes-Rivera, C Lenain, N Segal

Conference Proceedings  |  2021  |  Annals of Oncology

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

Frank P Lin, Subotheni Thavaneswaran, John P Grady, Mandy Ballinger, Maya Kansara, Samantha R Oakes, Jayesh Desai, Chee Khoon Lee, John Simes, David M Thomas

Journal article  |  2021  |  NPJ PRECISION ONCOLOGY

While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world i..

Overall survival (OS) with encorafenib (enco) cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Scott Kopetz, Dan Aderka, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Singh Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Adele Golden, Michelle L Edwards, Josep Tabernero

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

3583 Background: Enco + cetux (doublet) has been approved in the US, EU, and Japan for the treatment of BRAF V600E-mutant mCRC af..

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

Johanna C Bendell, Patricia LoRusso, Michael J Overman, Anne M Noonan, Dong-Wan Kim, John Strickler, Sang-We Kim, Stephen John Clarke, Thomas J George, Peter S Grimison, Minal A Barve, Manik A Amin, Jayesh Desai, Trisha Wise-Draper, Zachary Cooper, Nairouz Elgeioushi, Nancy Kathryn Mueller, Rakesh Kumar, Kevin YuFeng Wu, Sandip Pravin Patel

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

9047 Background: Upregulation of CD73 in multiple cancers increases adenosine production, leading to local immunosuppression. Ole..

Comparing survival outcomes for advanced cancer patients who access comprehensive genomic sequencing using a registry-based synthetic control arm.

Sophie O Haire, Koen Degeling, Fanny Franchini, Ben Tran, Stephen James Luen, Kortnye Maureen Smith, Stephen B Fox, Jayesh Desai, Maarten J IJzerman

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

e18851 Background: Studies evaluating the clinical benefit from Comprehensive Genomic Sequencing (CGS) in cancer patients (pts) h..

Global BRAF testing practices in metastatic colorectal cancer (mCRC).

Jayesh Desai, Scott Kopetz, Axel Grothey, Fortunato Ciardiello, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet Singh Wasan, Rona Yaeger, Takayuki Yoshino, Ashwin Gollerkeri, Michelle L Edwards, Montessa Rodriguez Lizaso, Josep Tabernero

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

e15523 Background: The BRAF V600E mutation is a marker of poor prognosis in patients with mCRC. Targeted therapy, such as encoraf..

BREAKWATER: Randomized phase 3 study of encorafenib (enco) cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

Scott Kopetz, Axel Grothey, Rona Yaeger, Fortunato Ciardiello, Jayesh Desai, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Michelle L Edwards, Adele Golden, Ashwin Gollerkeri, Josep Tabernero

Journal article  |  2021  |  Journal of Clinical Oncology

TPS3619 Background: Approximately 10% of patients (pts) with mCRC have BRAF mutations (mostly V600E). 1L tx options for BRAFV600E..

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

Scott Kopetz, Danielle A Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Axel Grothey, Eric Van Cutsem, Harpreet Singh Wasan, Rona Yaeger, Takayuki Yoshino, Amber C Donahue, Adele Golden, Ashwin Gollerkeri, Zhou Zhu, Josep Tabernero

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

3513 Background: Encorafenib + binimetinib + cetuximab (enco/bini/cetux; triplet) and enco + cetux (doublet) regimens improved ov..